RIP3 A composition for anti-cancer adjuvant comprising a RIP3 expression inducing agent or activator
The present invention relates to an anti-cancer adjuvant pharmaceutical composition and an anti-cancer pharmaceutical composition for enhancing reactivity to anti-cancer drugs, which contain a receptor-interacting protein kinase-3 (RIP3) expression accelerator or activator as an active component. In...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | The present invention relates to an anti-cancer adjuvant pharmaceutical composition and an anti-cancer pharmaceutical composition for enhancing reactivity to anti-cancer drugs, which contain a receptor-interacting protein kinase-3 (RIP3) expression accelerator or activator as an active component. In a combination therapy of co-administrating the RIP3 expression accelerator or activator with anti-cancer drugs, the present invention provides a novel use of the anti-cancer adjuvant pharmaceutical composition in which cancer cells can exhibit improved reactivity to the anti-cancer drugs.
본 발명은 RIP3 (Receptor-interacting protein kinase-3) 발현 촉진제 또는 활성화제를 유효성분으로 포함하는 항암제에 대한 반응성을 증진시키는 항암 보조용 약학 조성물 및 항암용 약학 조성물에 관한 것으로, RIP3 발현 촉진제 또는 활성화제와 항암제를 병용투여하는 병용 요법에 있어, 암세포가 항암제에 대해 개선된 반응성을 나타낼 수 있는 항암 보조용 약학 조성물의 신규 용법을 제공한다. |
|---|